Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

The Utility of FDG-PET for Radiation Treatment in NSCLC

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00385164
Recruitment Status : Unknown
Verified August 2011 by AHS Cancer Control Alberta.
Recruitment status was:  Recruiting
First Posted : October 6, 2006
Last Update Posted : July 25, 2017
Sponsor:
Collaborator:
Calgary Health Region
Information provided by (Responsible Party):
AHS Cancer Control Alberta

Tracking Information
First Submitted Date October 4, 2006
First Posted Date October 6, 2006
Last Update Posted Date July 25, 2017
Study Start Date October 2006
Primary Completion Date Not Provided
Current Primary Outcome Measures Not Provided
Original Primary Outcome Measures Not Provided
Change History
Current Secondary Outcome Measures Not Provided
Original Secondary Outcome Measures Not Provided
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title The Utility of FDG-PET for Radiation Treatment in NSCLC
Official Title The Utility of 18-Fluorodeoxyglucose Positron Emission Tomography (FDG-PET) for Radiation Treatment Planning in Non-Small Cell Lung Cancer (NSCLC)
Brief Summary Patients planned for radical radiation for NSCLC will undergo conventional CT stimulation and also PET/CT scans for definition of radiation target volumes
Detailed Description Not Provided
Study Type Observational
Study Design Observational Model: Cohort
Time Perspective: Prospective
Target Follow-Up Duration Not Provided
Biospecimen Not Provided
Sampling Method Non-Probability Sample
Study Population Non-small cell lung cancer
Condition
  • Lung Neoplasms
  • Positron Emission Tomography
Intervention Procedure: PET/CT scan for RT planning
Study Groups/Cohorts Not Provided
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status Unknown status
Estimated Enrollment
 (submitted: July 9, 2010)
50
Original Enrollment
 (submitted: October 4, 2006)
20
Study Completion Date Not Provided
Primary Completion Date Not Provided
Eligibility Criteria

Inclusion Criteria:

  • Non-small cell lung cancer to receive radical radiation

Exclusion Criteria:

  • unable to tolerate PET/CT scan
Sex/Gender
Sexes Eligible for Study: All
Ages 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers No
Contacts Contact information is only displayed when the study is recruiting subjects
Listed Location Countries Canada
Removed Location Countries  
 
Administrative Information
NCT Number NCT00385164
Other Study ID Numbers 20328
E-20328
Has Data Monitoring Committee Not Provided
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement Not Provided
Responsible Party AHS Cancer Control Alberta
Study Sponsor AHS Cancer Control Alberta
Collaborators Calgary Health Region
Investigators
Principal Investigator: Harold P Lau, MD AHS Cancer Control Alberta
PRS Account AHS Cancer Control Alberta
Verification Date August 2011